REG - ValiRx PLC - Inaphaea Deal Extension With Dominion

ValiRxAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250512:nRSL2312Ia&default-theme=true

RNS Number : 2312I  ValiRx PLC  12 May 2025

 

ValiRx PLC

("ValiRx" or the "Company")

 

Inaphaea Deal Extension With Dominion

London, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on
early-stage cancer therapeutics and women's health, is pleased to provide the
following update on the commercial activity of its wholly owned subsidiary
Inaphaea BioLabs ("Inaphaea").

Inaphaea is pleased to announce that it has signed an extension to the
evaluation and commercial use agreement with UK based Dominion Biotech Ltd
("Dominion") announced on 30 April 2025. Under the extension, Inaphaea will
share access to results from a proprietary screen of approximately 3000 FDA
approved drugs ("3k Screen") generated in a panel of Patient Derived Cells.
The drugs are approved for non-cancer applications and Dominion will mine the
data for potential cancer applications, carrying out routine analysis to
validate the most promising candidates at its own expense; the parties will
agree and share any additional in-depth studies if required. The results of
the analysis will be jointly owned and both parties will share equally all
costs associated with filing, prosecution and maintenance of any arising
patents for any repurposed drugs.

The parties will work together to commercialise any new assets either to the
owner of the original drug compounds or alternative companies interested in
the repurposed assets. Both companies will be free to pursue further research
and development projects based on the findings. All revenues generated from
this arrangement shall be equally shared after directly attributable costs.

 

Mark Eccleston, CEO of ValiRx commented "This is an excellent opportunity to
unlock additional value from existing data sets acquired with our biobank. We
believe there could be significant untapped potential for drug repurposing
within this data set which can be realised at a minimal cost by working with
our new partner, Dominion. Whilst ValiRx remains committed to its model of
evaluation and in-licensing of novel assets, we will leverage all potential
value from our assets, including our extensive data sets, particularly where
we can achieve some quick wins from established drugs with validated safety
profiles.  We are pleased to be able to extend our initial agreement with
Dominion and look forward to further opportunities to build value through our
collaboration."

 

Anthony Holmes, CEO of Dominion commented "This collaboration with Inaphaea
represents an exciting opportunity to unlock hidden value in existing approved
drugs. By analysing Inaphaea's extensive drug screening database against
patient-derived cancer models, we aim to identify novel cancer applications
for established compounds. This approach could significantly accelerate the
development timeline for new cancer treatments, as these drugs have already
cleared important safety hurdles. Dominion is committed to applying our
analytical expertise to this valuable dataset, potentially creating win-win
opportunities for pharmaceutical companies while ultimately providing cancer
patients with entirely new treatment options that would otherwise not exist."

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the
European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company
take responsibility for this announcement.

 

*** ENDS ***

Engage with the ValiRx management team directly by asking questions, watching
video
summaries and seeing what other shareholders have to say. Navigate to
our Interactive Investor
hub here: https://valirx.com/s/cc8ef3

For more information, please contact:

 

 Investor questions on this announcement           https://valirx.com/link/VyEObr

 We encourage all investors to share questions

 on this announcement via our investor hub
 ValiRx plc                                        Tel: +44 115 784 0025

                                                   www.valirx.com (http://www.valirx.com)

 Dr Mark Eccleston, CEO                            Mark.Eccleston@valirx.com

 Cairn Financial Advisers LLP (Nominated Adviser)  Tel: +44 (0) 20 7213 0880

 Liam Murray / Ludovico Lazzaretti

 Shard Capital Partners LLP (Sole Broker)          Tel: +44 (0) 20 7186 9000

 Damon Heath

 V Formation (Public Relations)                    +44 (0) 115 787 0206

                                                   www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                               lucy@vformation.biz

                                                   sue@vformation.biz

 

Subscribe to our news alert service: https://valirx.com/s/f298d1
(https://valirx.com/s/f298d1)

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCZZGMKNMRGKZM